According to an article published in Nature Medicine , trastuzumab deruxtecan showed high intracranial response rates in patients with active brain metastases associated with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, warranting its further clinical exploration.

The clinical trial enrolled 15 patients with HER2-positive breast cancer and newly diagnosed...